Analytical Tool - Protein Kinase Inhibitors in Oncology

"Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors (PKIs) for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:

• Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others
  
• Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2012*
  

The Package Includes

• A progress analysis on current and emerging drugs
• Information on most companies active in the development of PKIs in oncology
• Information on key industry related PKI drug projects in oncology
• Data from most important clinical trials
• Information on early developmental stage projects
• Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

• Tracking cutting edge companies, therapies and new technologies
• Rapid identification of partners & competitors
• Laying down a comprehensive framework for further analysis of the field
• Producing presentations surrounding the development of PKI drugs in oncology
• Identifying emerging PKI cancer products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of PKI drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.